Phase I/II Trial of Multi-Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas

被引：5
|
作者：
Chang, Lung-Ji [1 ,2 ,3 ]
Li, Yuhua [4 ]
Tu, Sanfang [4 ]
Lai, Xun [5 ,6 ]
Huang, Rui [4 ]
Tsao, Shih-Ting [1 ]
Liu, Yu-Chen [1 ]
Zhang, Rui [1 ]
Deng, Lan [4 ]
Zhou, Xuan [4 ]
Zhang, Hongyu [7 ]
Zhang, Wenli [7 ]
Li, Yuchen [1 ]
机构：
[1] Genoimmune Med Inst, Shenzhen, Peoples R China
[2] UESTC, Sch Med, Chengdu, Sichuan, Peoples R China
[3] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL USA
[4] Southern Med Univ, Zhujiang Hosp, Dept Hematol, Guangzhou, Guangdong, Peoples R China
[5] Kunming Med Univ, Affiliated Hosp 3, Yunnan Canc Hosp, Dept Hematol, Kunming, Yunnan, Peoples R China
[6] Yunnan Boya Hosp, Dept Hematol, Kunming, Yunnan, Peoples R China
[7] Peking Univ, Shenzhen Hosp, Shenzhen, Peoples R China
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-114396
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
225
引用
收藏
页数：3
相关论文
共 50 条
  • [21] CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS DIRECTED AGAINST CD19 (CTL019) INDUCE CLINICAL RESPONSES IN PATIENTS WITH RELAPSED OR REFRACTORY CD19+LYMPHOMAS
    Levine, B.
    Svoboda, J.
    Nasta, S. D.
    Porter, D.
    Chong, E.
    Lacey, S.
    Mahnke, Y.
    Melenhorst, J.
    Chew, A.
    Shah, G.
    Hasskar, J.
    Wasik, M.
    Landsburg, D.
    Mato, A.
    Garfall, A.
    Frey, N.
    Shaw, P.
    Marcucci, K.
    Shea, J.
    McConville, H.
    Manvar, N.
    O'Rourke, M.
    Lamontagne, A.
    Bersenev, A.
    Zheng, Z.
    Schuster, S.
    June, C.
    CYTOTHERAPY, 2015, 17 (06) : S13 - S13
  • [22] Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL
    Porter, David L.
    Frey, Noelle V.
    Melenhorst, Jan J.
    Hwang, Wei-Ting
    Lacey, Simon F.
    Shaw, Pamela A.
    Chew, Anne
    Marcucci, Katherine
    Gill, Saar
    Loren, Alison W.
    Mato, Anthony R.
    Schuster, Stephen J.
    Lledo, Lester
    McConville, Holly
    Gilmore, Joan
    Capobianchi, James
    Kalos, Michael D.
    Grupp, Stephan A.
    Levine, Bruce
    June, Carl H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+Lymphomas
    Schuster, Stephen J.
    Svoboda, Jakub
    Nasta, Sunita Dwivedy
    Porter, David L.
    Chong, Elise A.
    Landsburg, Daniel J.
    Mato, Anthony R.
    Lacey, Simon F.
    Melenhorst, Jan J.
    Chew, Anne
    Hasskarl, Jens
    Shah, Gaurav D.
    Wasik, Mariusz A.
    Marcucci, Katherine T.
    Zheng, Zhaohui
    Levine, Bruce L.
    June, Carl H.
    BLOOD, 2015, 126 (23)
  • [24] Chimeric Antigen Receptor 4SCAR-GD2/CD56-Modified T Cells in the Refractory and Recurrent Paediatric Solid Tumors
    Zhao, W.
    Dong, L.
    Wang, H.
    Zheng, X.
    Zhang, C.
    Wang, K.
    Zhu, G.
    Wang, B.
    Qin, M.
    Liu, Y.
    Zhang, D.
    Jin, M.
    Zheng, H.
    Zhang, L.
    Ma, X.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S38 - S38
  • [25] MANAGING RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) PATIENTS ON A PHASE I TRIAL RECEIVING AUTOLOGOUS CAR (CHIMERIC ANTIGEN RECEPTOR) T-CELLS GENETICALLY MODIFIED TO TARGET B CELL SPECIFIC ANTIGEN CD19
    Quintanilla, Hilda S.
    Miale-Mayer, Donna
    Llerandi, Diane
    ONCOLOGY NURSING FORUM, 2014, 41 (02) : E102 - E103
  • [26] CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS FOR RELAPSED, REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
    Melenhorst, J. Joseph
    Porter, David L.
    Lacey, Simon F.
    Loren, Alison W.
    Jemison, Christina
    Gilmore, Joan
    McConville, Holly
    Capobianchi, James
    Lledo, Lester
    Chew, Anne
    Zheng, Zhaohui
    Levine, Bruce L.
    June, Carl H.
    LEUKEMIA RESEARCH, 2014, 38 : S12 - S12
  • [27] Chimeric antigen receptor-modified T cells directed against CD19 in patients with relapsed or refractory CD19-positive B-cell lymphomas: interim analysis of a phase 1 study
    Ying, Zhitao
    Xiang, Xiaoyu
    Song, Yuqin
    Ding, Ning
    Lin, Yufu
    Zheng, Wen
    Wang, Xiaopei
    Lin, Ningjing
    Tu, Meifeng
    Xie, Yan
    Zhang, Chen
    Liu, Weiping
    Deng, Lijuan
    Liu, Yanling
    Yue, Yunqiang
    Yu, Xueyun
    Liu, Hanzhi
    Duan, Panpan
    Mamuti, Mierzhati
    Guo, Xiaokai
    Chen, Feng
    Wu, Xiaoyan
    Zhang, Junqing
    Zhang, Tingting
    Huang, Xue F.
    Jones, Lindsey
    Kang, Xi
    Chen, Si-Yi
    Zhu, Jun
    LANCET ONCOLOGY, 2017, 18 : S9 - S9
  • [28] Superior Therapeutic Efficacy of Chimeric Antigen Receptor Modified T Cells Against CD19 over Chemotherapy in Relapsed/Refractory Acute Lymphocytic Leukemia
    Hu, Yongxian
    Yu, Jian
    Luo, Yi
    Shi, Jimin
    Wu, Zhao
    Wei, Guoqing
    Sun, Jie
    Cai, Zhen
    Xiao, Lei
    Huang, He
    BLOOD, 2016, 128 (22)
  • [29] First-In-Patient Proof of Safety and Efficacy of a 4th Generation Chimeric Antigen Receptor-Modified T Cells for the Treatment of Relapsed or Refractory CD30 Positive Lymphomas
    Ying, Zhi-Tao
    Chang, Lung-Ji
    Kuo, Hao-Hsiang
    Liu, Yu-Chen
    Song, Yu-Qin
    Wang, Xiao-Pei
    Liu, Wei-Ping
    Zheng, Wen
    Xie, Yan
    Lin, Ning-Jing
    Tu, Mei-Feng
    Ping, Ling-Yang
    Zhang, Chen
    Huang, Hui-Ying
    Zhu, Jun
    MOLECULAR THERAPY, 2015, 23 : S164 - S164
  • [30] Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial
    Liu, Yang
    Guo, Yelei
    Wu, Zhiqiang
    Feng, Kaichao
    Tong, Chuan
    Wang, Yao
    Dai, Hanren
    Shi, Fengxia
    Yang, Qingming
    Han, Weidong
    CYTOTHERAPY, 2020, 22 (10) : 573 - 580
12345